Nelipepimut-S

• CAT Number: I033148
• CAS Number: 160212-35-1
• Molecular Formula: C50H78N10O11
• Molecular Weight: 995.23
• Purity: 98%
• Synonyms: Nelipepimut-S; NeuVax; NeuVax vaccine; E75 peptide
• Target: Protein Tyrosine Kinase/RTK
• Solubility: Soluble in DMSO
• Appearance: Solid powder
• Storage: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
• IUPAC Name: L-lysyl-L-isoleucyl-L-phenylalanylglycyl-L-seryl-L-leucyl-L-alanyl-L-phenylalanyl-L-leucine
• InChI: InChI=1S/C50H78N10O11/c1-8-31(6)42(60-44(64)35(52)21-15-16-22-51)49(69)58-37(25-33-17-11-9-12-18-33)45(65)53-27-41(62)55-40(28-61)48(68)57-36(23-29(2)3)46(66)54-32(7)43(63)56-38(26-34-19-13-10-14-20-34)47(67)59-39(50(70)71)24-30(4)5/h9-14,17-20,29-32,35-40,42,61H,8,15-16,21-28,51-52H2,1-7H3,(H,53,65)(H,54,66)(H,55,62)(H,56,63)(H,57,68)(H,58,69)(H,59,67)(H,60,64)(H,70,71)/t31-,32-,35-,36-,37-,38-,39-,40-,42-/m0/s1
• InChIKey: AHOKKYCUWBLDST-QYULHYBRSA-N
• SMILES: CC(C)C[C@@H](C(O)=O)NC([C@H](CC1=CC=CC=C1)NC([C@H](C)NC([C@H](CC(C)C)NC([C@H](CO)NC(CNC([C@H](CC2=CC=CC=C2)NC([C@H]([C@@H](C)CC)NC([C@H](CCCCN)N)=O)=O)=O)=O)=O)=O)=O)=O

Nelipepimut-S is an immunogenic peptide from the HER2 protein that is highly expressed in breast cancer.

Reference

1: Schneble EJ, Berry JS, Trappey FA, Clifton GT, Ponniah S, Mittendorf E, Peoples GE. The HER2 peptide nelipepimut-S (E75) vaccine (NeuVax™) in breast cancer patients at risk for recurrence: correlation of immunologic data with clinical response. Immunotherapy. 2014;6(5):519-31. doi: 10.2217/imt.14.22. Review. PubMed PMID: 24896623.
2: Mittendorf EA, Clifton GT, Holmes JP, Schneble E, van Echo D, Ponniah S, Peoples GE. Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients. Ann Oncol. 2014 Sep;25(9):1735-42. doi: 10.1093/annonc/mdu211. Epub 2014 Jun 6. PubMed PMID: 24907636; PubMed Central PMCID: PMC4143091.
3: Clifton GT, Peoples GE, Mittendorf EA. The development and use of the E75 (HER2 369-377) peptide vaccine. Future Oncol. 2016 Jun;12(11):1321-9. doi: 10.2217/fon-2015-0054. Epub 2016 Apr 5. PubMed PMID: 27044454.
4: Clifton GT, Gall V, Peoples GE, Mittendorf EA. Clinical Development of the E75 Vaccine in Breast Cancer. Breast Care (Basel). 2016 Apr;11(2):116-21. doi: 10.1159/000446097. Epub 2016 Apr 26. Review. PubMed PMID: 27239173; PubMed Central PMCID: PMC4881244.